| Literature DB >> 32854677 |
Hasan Oğuz Kapicibasi1, Hasan Ali Kiraz2, Nazli Demir Gök3.
Abstract
BACKGROUND: Hydroxyethyl Starch (HES) 130/0.4 (6%) is a commonly used intravascular volume expander with anti-inflammatory and antioxidant properties. In this study, we aimed to compare the histopathologic activity of HES 130/0.4 (6%) with various widely-used agents in pleurodesis.Entities:
Keywords: Hydroxyethyl starch; Parietal-visceral pleura; Pleurodesis
Mesh:
Substances:
Year: 2020 PMID: 32854677 PMCID: PMC7450802 DOI: 10.1186/s12890-020-01260-1
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1The surgical procedure. Cannulation (a) and blood tapping (b) from the subclavian vein for autologous pleurodesis
Fig. 2Study flow chart
Comparison of pleural adhesion levels between the experimental groups
| Control ( | PI ( | Talc ( | AB ( | HES ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Normal pleura | 8a | 100 | 0b | 0 | 0b | 0 | 0b | 0 | 4c | 50 |
| Adhesions at several sites | 0a | 0 | 2a, b | 33.3 | 0a | 0 | 0a | 0 | 4b | 50 |
| Widely dispersed adhesion | 0a | 0 | 4b | 66.7 | 6b | 85.7 | 4b | 57.1 | 0a | 0 |
| Complete adherence | 0a | 0 | 0a, b | 0.0 | 1a, b | 14.3 | 3b | 42.9 | 0a | 0 |
Pearson Chi-square test with subset comparison for column proportions. Chi-Square = 48.816, p < 0.001. Percentages represent column proportion. The same letters indicate the lack of significant difference from other group subsets (No correction for multiple hypothesis testing)
Fig. 3Macroscopic appearances in the different groups. a Macroscopic appearance in the SF group. b Macroscopic appearance in the povidone-iodine group. c Macroscopic appearance in the autologous pleurodesis group. d Macroscopic appearance in the sterile talcum group. e Macroscopic appearance in the HES 130/0.4 (6%) group
Comparison of inflammation levels between the experimental groups
| Control ( | PI ( | Talc ( | AB ( | HES ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Non-existent | 7a | 87.5 | 0b | 0 | 0b | 0 | 0b | 0 | 3b | 37.5 |
| Inflammation between > 0–5% | 1a | 12.5 | 3a. b | 50 | 3a. b | 42.9 | 2a. b | 28.6 | 5b | 62.5 |
| Inflammation between > 5–30% | 0a | 0 | 3b | 50 | 4b | 57.1 | 3b | 42.9 | 0a | 0.0 |
| Inflammation between > 30–100% | 0a | 0 | 0a | 0 | 0a | 0 | 2a | 28.6 | 0a | 0.0 |
Pearson Chi-square test with subset comparison for column proportions. Chi-Square = 35.633, p < 0.001. Percentages represent column proportion. The same letters indicate the lack of significant difference from other group subsets (No correction for multiple hypothesis testing)
Comparison of fibrosis levels between the experimental groups
| Control ( | PI ( | Talc ( | AB ( | HES ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| No fibrosis (0%) | 8a | 100 | 0b | 0 | 1b | 14.3 | 0b | 0 | 8a | 100 |
| Fibrosis between > 0–5% | 0a | 0 | 6b | 100 | 4b | 57.1 | 5b | 71.4 | 0a | 0 |
| Fibrosis between > 5–30% | 0a | 0 | 0a | 0 | 2a | 28.6 | 2a | 28.6 | 0a | 0 |
Pearson Chi-square test with subset comparison for column proportions. Chi-Square = 36.928, p < 0.001. Percentages represent column proportion. The same letters indicate the lack of significant difference from other group subsets (No correction for multiple hypothesis testing)
Fig. 4Microscopic evaluations in the different groups. a: Sterile Talcum group; Development of fibrosis in the visceral pleura (arrow) and emphysematous changes in the subpleural area. H&E, × 100. b: Autologous blood transfusion group; Development of mild fibrosis in the visceral pleura around intense parenchymal inflammation areas (arrow). H&E, × 100. c: HES 130/0.4 (6%) group; Intense inflammatory response and mild emphysematous changes, H&E, × 100
Detailed evaluation of previous experimental animal studies (rats and rabbits) of pleurodesis
| Agent | Study | Species | Dosage | Duration | Toxicity | Notes |
|---|---|---|---|---|---|---|
| Povidone-iodine | Teixeira et al. 2013 [ | New Zealand rabbits (2–3 kg) | 2 ml @ 2, 4 and 10% | 1, 3, 7, 14, 28 days | No adverse effects despite relatively high dosage | Macroscopic results showed progressive increase in adhesion with dosage (4 and 10%) and time (demonstrating a plateau after 7 days) |
| Lashkarizadeh et al. 2019 [ | Rats (details not understood) | 0.5 ml @ 8% | 45 days | No information | Povidone-iodine had similar effectivity with Talc. | |
| Yazkan et al. 2013 [ | Wistar-albino rats (260–320 g) | 2 ml @ 1, 2 and 4% | 30 days | Although 4% dosage demonstrated some microscopic adverse effects in the contralateral pleura, statistical significance was not present. | 2 and 4% dosage deemed to be similar in effect, and both were better than 1%. All three concentrations were deemed safe, but 2% was advised. | |
| Talc | Vanucci et al. 2018 [ | New Zealand rabbits (2.1–2.5 kg) | 2 ml @ 40 mg/kg and 200 mg/kg | 14 and 28 days | Pleural granulomas were observed with both doses in all subjects on day 14. In the 40 mg/kg group, only 40% of the subjects had granulomas on the 28th day. All 200 mg/kg recipients had granulomas on the 28th day. | Adhesion did not seem to increase with higher dosage, but somewhat increased with time (14 vs. 28 days) |
| Gozubuyuk et al. 2010 [ | Wistar-albino rats (280–320 g) | 0.5 ml @ 60 mg/kg | 72 h and 7 days | Significant alveolar edema, hemorrhage and inflammation in the acute phase (72 h) compared to tetracycline and controls. At 7 days, edema was also present at a higher frequency. | Results were compared with tetracycline, and showed that Talc caused earlier pleural proliferation and fibrosis. | |
| Ahn et al. 2015 [ | Sprague-Dawley rats (220–300 g) | 400 mg/kg (volume not reported) | 28 days | Talc particles not detected in lung parenchyma. Suggested possibility for systemic effect. | ||
| Muta et al. 2011 [ | Wistar rats (300–350 g) | 400 mg/kg (volume not reported) | 30 days | Talc particles detected in the alveoli. | ||
| Refosco et al. 2004 [ | Wistar rats (200–300 g) | 2 ml @ 100 mg/kg and 500 mg/kg | 45 days | Too few subjects to evaluate toxicity. | No remarkable differences between the two very different doses. | |
| Mitchem et al. 1999 [ | New Zealand rabbits (4 kg) | ~ 0.25 ml @ 70 mg/kg | 30 days | Histological changes in the contralateral lung and blood chemistry changes. Suggested systemic adverse effect. | Although adverse effects were observed, authors concluded Talc was safer than doxycycline (other group). | |
| Autologous Blood | Ozpolat et al. 2010 [ | Wistar-albino rats (280–310 g) | 1 ml/kg, 2 ml/kg and 3 ml/kg | 30 days | No microscopic or macroscopic adverse effects in the contralateral pleura and other tissues. No systemic effects. | 1 ml/kg did not cause adhesion, 2 ml/kg was effective but 3 ml/kg was deemed more appropriate. |
| Yalcinkaya et al. 2019 [ | Wistar-albino rats (250–300 g) | 3 ml/kg | 7 and 21 days | At least 1 rat died before the end of the study in each group. | NSAIDs seemed to reduce the formation of pleurodesis when used after the intervention. | |
| Yildizhan et al. 2016 [ | Wistar-albino rats (260–320 g) | 2 ml/kg | 30 days | No inflammation or adhesion in the contralateral pleura, liver or diaphragm. No sign of alveolar injury. | A group which received a 50:50 mix of ozone and 1 ml/kg autologous blood demonstrated better results compared to autologous blood alone (2 ml/kg). | |
| Mitchem et al. 1999 [ | New Zealand rabbits (4 kg) | 1 ml/kg | 30 days | No adverse effects. | No efficacy in contrast to Talc and doxycycline which had significant efficacy. |